Stable Coronary Artery Disease Clinical Trial
— RESPONDOfficial title:
A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND]
Verified date | August 2011 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated the effect of Ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.
Status | Completed |
Enrollment | 98 |
Est. completion date | March 2009 |
Est. primary completion date | March 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with documented stable Coronary Artery Disease (CAD) (stable angina, previous MI history, previous history of revascularization) - Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception Exclusion Criteria: - History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (CABG)) - Any acute or chronic unstable condition in the past 30 days - Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma - History of intolerance or allergy to aspirin or clopidogrel |
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Research Site | Hamilton | Ontario |
Canada | Research Site | Lachine | |
Denmark | Research Site | Aalborg | |
Denmark | Research Site | Arhus | |
Denmark | Research Site | Esbjerg | |
United Kingdom | Research Site | Sheffield | |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Jonesboro | Arkansas |
United States | Research Site | Ormond Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Canada, Denmark, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.) | The primary definition of response to treatment is IPA >10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Day 14 and Day 28, 4 Hrs Post Dose. | No |
Primary | Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop. | The secondary definition of response to treatment is IPA >50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Day 14, and day 28, 4 hours post dose | No |
Secondary | Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15 | IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. | Day 15, 4 hrs post switching | No |
Secondary | Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28 | IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. | 4 hrs post first dose on day 28 | No |
Secondary | Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15 | IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. | Day 15, 4 hrs post switching | No |
Secondary | Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28 | IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. | 4 hrs post first dose on day 28 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205425 -
Computed Tomography Coronary Angiography Before Stent Implantation
|
N/A | |
Completed |
NCT01243099 -
Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions
|
N/A | |
Completed |
NCT03312855 -
Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
|
Phase 2 | |
Recruiting |
NCT03089450 -
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
|
N/A | |
Completed |
NCT01523392 -
A Pharmacodynamic Study With Ticagrelor in African American Patients
|
Phase 4 | |
Completed |
NCT01209637 -
Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD
|
N/A | |
Active, not recruiting |
NCT04434365 -
Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00510588 -
Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease
|
N/A | |
Completed |
NCT03384966 -
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
|
Phase 2 | |
Active, not recruiting |
NCT01609465 -
Prognostic Models for People With Stable Coronary Artery Disease
|
N/A | |
Terminated |
NCT00911339 -
Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents
|
Phase 3 | |
Completed |
NCT00984802 -
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
|
Phase 2 | |
Completed |
NCT03782688 -
Precise Percutaneous Coronary Intervention Plan (P3) Study
|
||
Completed |
NCT02580851 -
Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention
|
N/A | |
Recruiting |
NCT03313752 -
Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
|
Phase 3 | |
Completed |
NCT01184300 -
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
|
Phase 2/Phase 3 | |
Completed |
NCT01523366 -
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
|
Phase 4 | |
Completed |
NCT01118325 -
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
|
Phase 2 | |
Recruiting |
NCT06123728 -
MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease
|